GEN Exclusives

More »

The Lists

More »
Dec 18, 2012

Top 20 Venture Capital Firms

Who invests the most funds in the most biotech companies?

Top 20 Venture Capital Firms

These firms have invested the most venture capital or other equity in early- to late-stage biotechnology and pharma companies. [Bobby4237 - Fotolia.com]

  • In order to start up a company, one must have capital, and for some companies, a venture capital firm may be the best source for it. Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies? Below is a list of top venture capital firms and broader financial firms that invest venture capital or other equity in early- to late-stage biotechnology and pharmaceutical companies, ranked by total capital under management or, for some firms, total active “committed” capital from funds in use.

  • #20. Enterprise Partners

    Location(s): La Jolla, CA

    Fund size and status: More than $1.1 billion under management across six funds. Current fund: $353 million EPVI, closed 2001

    Biopharma portfolio companies: Ascenta Therapeutics, Celladon, Celula, Complete Genomics

    Typical investment range: Initial investment more typically ranges between $3 million and $10 million, with additional funds reserved for follow-on financings. Occasionally the partnership will invest as little as $300K in a seed stage venture. Preference for investing in California-based businesses

    Year established: 1985

  • #19. ARCH Venture Partners

    Location(s): Chicago; Austin, TX; Seattle; San Francisco; Dublin

    Fund size and status: Nearly $1.5 billion under management across seven funds. Current fund: $400 million ARCH Venture Fund VII, closed 2007

    Biopharma portfolio companies: Achaogen, Acylin Therapeutics, Agios Pharmaceuticals, Allozyne, Alnylam Holdings, Array BioPharma, BIND Biosciences, bluebird bio, Caliper Life Sciences, Cambrios Technologies, Chiasma, Ensemble Therapeutics, Fate Therapeutics, GenVec, Groove BioPharma, Hua Medicine, Ikaria, Illumina, ISB Accelerator, Kythera Biopharma, Limerick BioPharma, Lycera, NeurogesX, Nura, Omeros, Oncofactor, Permeon Biologics, PhaseRx, Pulmatrix, Receptos, Sorbent therapeutics, Theraclone Sciences, VBI Vaccines, VentiRx, VLST, Xcyte, XenoPort, XORI

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1986 as not-for-profit ARCH Development Corp. by University of Chicago

  • #18. Burrill & Co.

    Location(s): San Francisco

    Fund size and status: $1.5 billion under management across eight funds. Current fund: $505 million Burrill Capital Fund IV, closed for second time August 2012

    Biopharma portfolio companies: Acusphere, Adlyfe, Adma Biologics, Catalyst Biosciences, Captaris Therapeutics, Chromatin, Lentigen, Logical Therapeutics, MabVax Therapeutics, Neos Therapeutics, Neurotech, Newbridge Pharmaceuticals, Nora Therapeutics, Odyssey Thera, OncoGeneX, Scynexis, Waterstone Pharmaceuticals, XDx

    Typical investment range: $5 million to $15 million over the life of a company

    Year established: 1994

  • #17. Advanced Technology Ventures

    Location(s): Palo Alto, CA, and Boston

    Fund size and status: $1.6 billion under management across eight funds. Current fund: $305 million ATV Fund VIII, closed 2007

    Biopharma portfolio companies: Acceleron Pharma, Calithera Biosciences, Catabasis Pharmaceuticals, Five Prime Therapeutics, Hydra Biosciences, Portola Pharmaceuticals, Second Genome, Thrasos Therapeutics, Verastem

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1979

  • #16. Versant Ventures

    Location(s): Menlo Park, CA; Newport Beach, CA; San Francisco; Basel, Switzerland

    Fund size and status: $1.6 billion in committed capital across three funds; raising funds for fifth fund, reported to be $250 million. Current fund: $500 million Versant Venture Capital IV L.P., closed 2008

    Biopharma portfolio companies: 5AM Ventures, Achaogen, Alexza Pharmaceuticals, Biotie Therapies, Five Prime Therapeutics, FLAP, Flexion Therapeutics, Fluidigm, Groove Biopharma (formerly Mirina), Helicos Biosciences, Immune Design, Inception 1, Inception 2, Inception 3, Metabolex, Okairos, OnGen, Panmira Pharmaceuticals, PathWork Diagnostics, PhaseRx, Quanticel Pharmaceuticals, RuiYi, Semprae Laboratories, Spark Diagnostics, Theraclone Sciences, Transcept Pharmaceuticals, Veracyte, Viral Logic Systems Technology (VLST).

    Typical investment range: Initial investments have started at $250,000; total investments have been as large as $30 million

    Year established: 1999

  • #15. HealthCare Ventures

    Location(s): Cambridge, MA

    Fund size and status: $1.6 billion under management across nine funds. Current fund: $250 million HealthCare Ventures IX L.P., closed 2010

    Biopharma portfolio companies: Aciex, Anchor Therapeutics, Anexon, Apellis Pharmaceuticals, Apofore, BIKAM Pharmaceuticals, Catalyst Biosciences, Cleveland HeartLab, DecImmune Therapeutics, Dekkun, Galleon Pharmaceuticals, GITR, GlobeImmune, InfaCare Pharmaceutical, Mosaic Biosciences, nanoMR, PathoGenetix, PharmAthene, Promedior, ProteoStasis Therapeutics, Radius Health, Seahorse Bioscience, Shape Pharmaceuticals, Stemgent, Synovex, Tensha Therapeutics, TetraLogic Pharmaceuticals, Theraclone Sciences, Threshold Pharmaceuticals, Trevena, VaxInnate, Vaxxas, Xanodyne Pharmaceuticals, Xencor

    Year established: 1985

  • #14. Frazier Healthcare Ventures

    Location(s): Seattle and Menlo Park, CA

    Fund size and status: More than $1.8 billion under management across six funds; raising funds for seventh fund, expected to be $400 million. Current fund: $600 million Frazier Healthcare VI, closed 2008

    Biopharma portfolio companies: Achaogen, Alcresta, Alexza Pharmaceuticals, Allena Pharmaceuticals, Amicus Therapeutics, Anaptys, Attercor, Cadence Pharmaceuticals, Chimerix, Clovis Oncology, Collegium Pharmac eutical, Incline Therapeutics, Kalidex Pharmaceuticals, Portola Pharmaceuticals, QuatRx, Rempex Pharmaceuticals, Silence Therapeutics, Silvergate Pharmaceuticals (formerly Intradigm), Tobira Therapeutics, VentiRx Pharmaceuticals

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1991

  • #13. SV Life Sciences

    Location(s): Boston; Foster City, CA; London

    Fund size and status: Approximately $2 billion under management across five funds. Current fund: $524 million SV Life Sciences Fund V, closed 2010. Fund includes $11 million $513m (plus $11 million of co-investments committed by partners and individuals affiliated with SVLS).

    Biopharma portfolio companies: Achillion Pharmaceuticals, Adimab, Affinium Pharmaceuticals, Alba Therapeutics, Alinea Pharmaceuticals, Allocure, Antiva, Archemix, Arsanis Biosciences, Autifony Therapeutics, Bicycle Therapeutics, Catabasis Pharmaceuticals, Cellzome, Convergence Pharmaceuticals, Cyterix Pharmaceuticals, Delenex Therapeutics, Good Start Genetics, Imagen Biotech, Itero Biopharmaceuticals, Kalvista Pharmaceuticals, Link Medicine, Logical Therapeutics, Lux Biosciences, Mpex Pharmaceuticals, NeurogesX, Neurotech, NKT Therapeutics, Ophthotech, PanOptica, Rempex Pharmaceuticals, Sutro Biopharma, TopiVert, Vantia Pharmaceuticals

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1993 as Schroder Ventures Life Sciences, part of the Schroder Ventures Group. SVLS became independent of the Schroder Ventures Group in 2001, and changed its name in 2005

  • #12. Alta Partners

    Location(s): San Francisco

    Fund size and status: $2 billion under management across eight funds. Current fund: $500 million Alta Partners VIII, closed 2006

    Biopharma portfolio companies: 7TM Pharma, Ablynx, AcelRx Pharmaceuticals, Achaogen, Aegerion Pharmaceuticals, Aerie Pharmaceuticals, Aerovance, Alba Therapeutics, Astex Pharmaceuticals, aTyr Pharma, Azelon Pharmaceuticals, Bioventus, Cara Therapeutics, Ceregene, Cerenis Therapeutics, ChemoCentryx, Chimerix, Corcept Therapeutics, Cytokinetics, DiscoveRx, Esperion Therapeutics, Excaliard Pharmaceuticals, Genedata, Immune Design , Innate Pharma, Intarcia Therapeutics, Kiadis Pharma, Lithera, MacroGenics, Metabolex, Nereus Pharmaceuticals, Pathwork Diagnostics, Portola Pharmaceuticals, Proacta Therapeutics, Prolacta Bioscience, SARcode, Scynexis, Silence Therapeutics, Sonexa Therapeutics, Sunesis Pharmaceuticals, Sutro Biopharma, Threshold Pharmaceuticals, Trevena, Veloxis, ViroBay, VitrOmics

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1996

  • #11. Morgenthaler Ventures

    Location(s): Menlo Park, CA; Boulder, CO; Boston; Cleveland; Princeton, NJ

    Fund size and status: $2.5 billion under management; raising funds for 10th fund, IT Fund X, reported to be $200 million. Current fund: $400 million Fund IX, closed 2008 and used in part for investment in life-sciences companies

    Biopharma portfolio companies: Calithera Biosciences, Catalyst Biosciences, Elcelyx Therapeutics, Galleon Pharmaceuticals, GlobeImmune, Mosaic Biosciences, OcoMed Pharmaceuticals, Orexigen, Principia, Promedior Pharmaceuticals, Ra Pharmaceuticals, Replidyne, Ribozyme Pharmaceuticals, Stemgent, Threshold Pharmaceutical, Tragara Pharmaceuticals, Trellis Bioscience, Vical

    Typical investment range: Between $12 million and $20 million over several rounds; majority of investments in Series A

    Year established: 1968


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?